Online Inquiry
HRAS (G12V/+) Cell Line
SPL-01660
| Size | Price |
| 1 Unit | Online Inquiry |
| Description |
|---|
| HRAS (G12V/+) |
| Target Information | |
|---|---|
| Target Name | HRAS |
| Gene Abbr. | HRAS |
| Gene ID | 3265 |
| Full Name | HRas proto-oncogene, GTPase |
| Alias | C-BAS/HAS, C-H-RAS, C-HA-RAS1, CTLO, H-RASIDX |
| Species | Human |
| Genomic Locus | 11p15.5 |
| Introduction | This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene. [provided by RefSeq, Jul 2008]. |
| Product Details | |
|---|---|
| Cell Line Model | SW48 |
| Genotype | HRAS (G12V/+) |
| Description | HRAS (G12V/+) |
| Parental ATCC ID | CCL-231 |
| STR Profile | Amelogenin: X; CSF1PO: 9,10; D13S317: 11, 12; D16S539: 11,13; D5S818: 10, 14; D7S820: 9, 10; THO1: 6,9.3; TPOX: 8; vWA: 18,20, 21; ATCC |
| Disease | Colorectal adenocarcinoma, Dukes Type C Grade IV |
| Tissue | Colon |
| Gender | Female |
| Key Endogenous Mutations | CTNNB1, FBXW7, EGFR |
| CVT Selection Condition | G418 resistant - 0.8 mg/mL |
| Cell Number | 2x10^6 |
| Handling Specifications | |
|---|---|
| Revival | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 70-80% confluency, approximately 1:3-1:6. Cells may experience a lag period of approximately 1 week before stable growth is achieved. |
| Culture Medium | RPMI 1640 including 2 mM L-glutamine and 25 mM sodium bicarbonate, supplemented with 10% FBS. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 70-80% confluency, approximately 1:3-1:6. Cells may experience a lag period of approximately 1 week before stable growth is achieved. |
| Freeze Medium | Complete growth media 45% + USDA approved FBS 50% + DMSO 5% |
| Biosafety Level | BSL-1 |
| Disclaimer | This product is classified under IATA regulations as a GMMO (genetically modified micro-organism) and will ship as UN3245. If applicable, ensure facility meets all requirements per local and country regulations. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.